Skip Navigation

Annals of Oncology 2009 20(5):799; doi:10.1093/annonc/mdp248
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

in this issue

in this issue

The first 10% of the full text of this article appears below.


   epidermal growth factor receptor as a therapeutic target in triple-negative breast cancer
 
Basal-like breast cancers are generally negative for expression of estrogen and progesterone receptors and HER-2 [triple-negative breast cancer (TNBC)] and express basal markers, such as cytokeratins 5/6 and epidermal growth factor receptor (EGFR). At present, no targeted therapy has proven benefit in TNBC, although targets are being sought. However, EGFR messenger RNA is detected more frequently and at higher levels in basal-like breast cancers, and in . . . [Full Text of this Article]


   docetaxel plus gemcitabine versus docetaxel in second-line treatment of non-small-cell lung cancer
 

   KRAS mutations and EGF61A>G polymorphism and the effect of cetuximab and irinotecan in metastatic colorectal cancer
 

   preventing anxiety or depressive disorders in cancer patients
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?